Related Experiment Video
Updated: Nov 29, 2025

13:47
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
3.7K
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States
Emerging Infectious Diseases
|November 23, 2020
Abstract:
The US Food and Drug Administration approved a 6-month regimen of pretomanid, bedaquiline, and linezolid for extensively drug-resistant or multidrug-intolerant tuberculosis after a trial in South Africa demonstrated 90% effectiveness 6 months posttreatment. We report on a patient who completed the regimen using a lower linezolid dose.
Keywords:
BPaLNix-TBUnited Statesantimicrobial resistancebacteriabedaquilinedrug monitoringlinezolidpretomanidtuberculosis and other mycobacteria
